secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2026-01-05T23:59:59+00:00
Accession:  0001193125-26-001502
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jade Biosciences reports $336M cash; outlines 2026 pipeline milestones including JADE101 Phase 2
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments ~$336M as of Dec 31, 2025; funds operations into H1 2028.
- JADE101 Phase 1 interim data expected H1 2026; Phase 2 in IgAN to start mid-2026 with preliminary data in 2027.
- JADE201 (anti-BAFF-R) first-in-human study in RA expected Q2 2026; interim data in 2027.
- JADE301 nominated; preclinical; Phase 1 expected H1 2027; details disclosed H2 2026.
- Company to present at J.P. Morgan Healthcare Conference on Jan 15, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000119312526001502/0001193125-26-001502-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000119312526001502/d93206d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-001502

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer